Mithraprabhu et al. analyzed the plasma-derived circulating free tumor DNA as an adjunct to bone marrow biopsies for mutational characterization (for KRAS, NRAS, BRAF, and TP53) and for tracking disease progression in 33 relapsed/refractory and 15 newly diagnosed MM patients, in comparison to 12 healthy donors by NGS, showing a higher amount of cfDNA in MM patients. The gene discussed is TP53; the disease is Miyoshi myopathy.